CD34+CD41DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Etablissment FrançIs Du Sang, Universite De Strasbourg
InventorsCatherine Strassel, Christian Gachet, François Lanza, Nathalie Brouard
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of producing CD34+CD4dim megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD4dim cells.
Claims15
An ex vivo method of producing proplatelet-bearing megakaryocytes (MKs) and/or platelets comprising:
- a) culturing an isolated CD34+CD9−CD41+ cell population of MK progenitors in a serum-free culture medium comprising thrombopoietin (TPO), in presence of an aryl hydrocarbon receptor (AhR) antagonist or by co-culture with human mesenchymal stromal cells (hMSCs), for a time sufficient to obtain a cell population comprising proplatelet-bearing MKs and/or platelets;
- and
- b) collecting said cell population comprising proplatelet-bearing MKs and/or platelets.
A method of producing megakaryocyte (MK) progenitor cells comprising:
- a0) culturing haematopoietic stem cells (HSC) in a serum-free culture medium comprising low-density lipoprotein (LDL), stem cell factor (SCF), TPO, IL-6 and IL-9, in presence of an aryl hydrocarbon receptor (AhR) antagonist or by co-culture with human mesenchymal stromal cells (hMSCs), for a time sufficient to obtain a cell population comprising CD34+CD9−CD41+ cells;
- and
- a1) isolating said CD34+CD9−CD41+ cells from said cell population.
Dependencies are inferred from the claim text.